CHNA
Loncar China BioPharma ETF
NAV as of
4 Week: 14.16 - 15.28
52 Week: 13.50 - 22.53
Latest Closing Price
14.21
Premium / Discount
-0.91
Expense Ratio
0.79%
Investment Objective
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -24.28 | 2.29 | -10.60 |
| 1 Day | -2.54 | 0.00 | 0.00 |
| 1 Week | -1.58 | 4.00 | -0.40 |
| 1 Month | -4.35 | 8.48 | -0.51 |
| 3 Months | -12.11 | 16.04 | -0.76 |
| 6 Months | -23.91 | 23.00 | -1.04 |
| 1 Year | -4.99 | 43.76 | -0.11 |
| 2 Years | -62.72 | 64.59 | -0.97 |
| 3 Years | -53.63 | 71.69 | -0.75 |
| 5 Years | -39.21 | 82.68 | -0.47 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 30.6631 | 34.3839 | -9.4178 | -28.0018 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 45.0000 | 48.0000 | 50.0000 | 68.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 28/12/2021 | 30/12/2021 | 3.0314 |
| 22/12/2019 | 25/12/2019 | 0.0403 |
Portfolio Data
Total Number of Holdings: 69
Number of Bond Holdings: 0
Number of Equity Holdings: 66
Total Market Value: 4,101,534
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | AIM Vaccine Co Ltd Class H | 3.7683 | 29,400 | 0 | 154,531 |
| 2 | Legend Biotech Corp ADR | 2.9392 | 1,841 | 0 | 120,530 |
| 3 | Wuxi AppTec Co Ltd | 2.7365 | 10,257 | 0 | 112,219 |
| 4 | Shanghai Haohai Biological Technology Co Ltd Shs - | 2.6989 | 18,200 | 0 | 110,675 |
| 5 | BeiGene Ltd ADR | 2.5822 | 507 | 0 | 105,892 |
| 6 | Sinopharm Group Co Ltd | 2.5695 | 36,700 | 0 | 105,368 |
| 7 | Shanghai Fosun Pharmaceutical (Group) Co Ltd Class | 2.3366 | 40,500 | 0 | 95,819 |
| 8 | Guangzhou Baiyunshan Pharmaceutical Holdings Co Lt | 2.1656 | 31,000 | 0 | 88,805 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 7.35 |
| Large | 35.86 |
| Medium | 35.14 |
| Small | 13.03 |
| Micro | 7.73 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
12.4265
Price/Book*
1.5840
Price/Sales*
1.0041
Price/Cash Flow*
9.4911
Dividend Yield*
1.7750
Growth Measures
Long-Term Earnings
12.8278
Historical Earnings
-0.3682
Sales Growth
6.3563
Cash-Flow Growth
-7.6622
Book-Value Growth
1.6775
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
